Gynecologic Cancer (Ovary, Peritoneal): Trametinib in Treating Patients With Recurrent
or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Which will work better to treat your low-grade serious ovarian or peritoneal cancer:
trametinib OR one of the standard treatments available that your doctor will choose
for you (either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin
[PLD], or topotecan)?
Basic Study Information
Purpose:Location: cancer center
In this study, you will get either the trametinib or one of the standard treatments
available. You will not get both at the same time.
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT02101788?term=NCT02101788&rank=1
Study Reference #: CGYO-16069
Lead Researcher (Principal Investigator)
Lead Researcher: Richard Moore
Study Contact InformationStudy Coordinator: Laura Mitchell
Phone: (585) 275-7763
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search